A replicating LCMV-based vaccine for the treatment of solid tumors.
adoptive cell transfer
cancer immunotherapy
melanoma
self-antigens
viral-vector-based vaccines
Journal
Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581
Informations de publication
Date de publication:
05 Dec 2023
05 Dec 2023
Historique:
received:
17
04
2023
revised:
31
10
2023
accepted:
30
11
2023
pubmed:
7
12
2023
medline:
7
12
2023
entrez:
7
12
2023
Statut:
aheadofprint
Résumé
Harnessing the immune system to eradicate tumors requires identification and targeting of tumor antigens, including tumor-specific neoantigens and tumor-associated self-antigens. Tumor-associated antigens are subject to existing immune tolerance, which must be overcome by immunotherapies. Despite many novel immunotherapies reaching clinical trials, inducing self-antigen-specific immune responses remains challenging. Here, we systematically investigate viral-vector-based cancer vaccines encoding a tumor-associated self-antigen (TRP2) for the treatment of established melanomas in preclinical mouse models, alone or in combination with adoptive T cell therapy. We reveal that, unlike foreign antigens, tumor-associated antigens require replication of lymphocytic choriomeningitis virus (LCMV)-based vectors to break tolerance and induce effective antigen-specific CD8
Identifiants
pubmed: 38058126
pii: S1525-0016(23)00659-7
doi: 10.1016/j.ymthe.2023.11.026
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests C.M.S. is a scientific advisor to, has stock options in, and has received research funding from Enable Medicine, Inc. L.F. is a founder and shareholder of Hookipa Pharma Inc. F.S., S.S., and K.K.O. are employees and stock option holder of Hookipa Pharma, Inc. L.F., S.S.R., S.S., and K.K.O. are listed as inventors of the patent entitled “Arenavirus particles to treat solid tumors” (patent number WO2018/185307 A1) describing the application of artLCMV vectors in the treatment of tumors.